Adzenys Xr-odt Tablet, Orally Disintegrating
Product Images NDC 70165-020

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Adzenys Xr-odt (NDC 70165-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Neos Therapeutics Brands, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Adzenys Xr Odt 1

FDA Label Image

Adzenys Xr Odt 2

This appears to be a chart showing the mean concentration (in ng/mL) of different types of amphetamines (Dextroamphetamine and Levoamphetamine) at different time intervals (in hours), as well as their respective extended release forms (Amphetamine XR-ODT and MAS ER).*

FDA Label Image

Adzenys Xr Odt 3

Adzenys XR-ODT is a medication that comes in the form of orally disintegrating tablets containing 3.1 mg of amphetamine per tablet. This medication is packaged in a container that includes 30 tablets (on 5 blister cards) and a travel case. The pharmacist should dispense the enclosed medication guide with each patient. The barcode NDC for this medication is 70165-005-30. The remaining text is not legible.*

FDA Label Image

Adzenys Xr Odt 4

This is a medication called Adzenys XR-ODT in the form of extended-release orally disintegrating tablets that contains 6.3 mg of amphetamine (equivalent to that in a 10 mg strength mixed salts of a single-entity amphetamine product). The medication guide should be dispensed to each patient for proper and safe use. It comes in a travel case along with 30 tables (5 x Scount blstr cad) and pharmacist's instructions. NDC code of the medicine is 70165-010-30 and it is Rx only.*

FDA Label Image

Adzenys Xr Odt 5

This is a description of a medication called Adzenys XR-ODT™. It is an orally disintegrating tablet that should not be crushed or chewed. This medication contains 9.4 mg of amphetamine which is equal to a 15 mg strength mixed salts of a single-entity amphetamine product. The package has a Medication Guide enclosed and is intended for dispensation by a pharmacist to a patient. The rest of the text appears to be illegible or not relevant to the description.*

FDA Label Image

Adzenys Xr Odt 6

Adzenys XR-ODT is a medication that comes in a package containing 30 orally disintegrating tablets of 125mg of amphetamine (equivalent to 20 mg mixed salts of a single-entity amphetamine product). The package includes five blister cards with six tablets each and a travel case. The medication guide enclosed in the package needs to be given to each patient. The drug should not be chewed or crushed. The product's NDC number is 70165-020-30. Dosage should be individualized and should be taken with caution. The rest of the text is not readable.*

FDA Label Image

Adzenys Xr Odt 7

This is a description of Adzenys XR-ODT, a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD). It comes in tablet form and contains 15.7 mg of amphetamine. It is an extended-release medication that dissolves quickly in the mouth and should not be chewed or crushed. The package contains 30 tablets and a medication guide for patients. The National Drug Code (NDC) for Adzenys XR-ODT is 7016502530.*

FDA Label Image

Adzenys Xr Odt 8

This is a medication called Adzenys XR-ODT, which comes in the form of orally disintegrating tablets to treat ADHD. Each tablet contains 188mg of amphetamine, equivalent to a 30 mg strength mixed salts 18.8mg, and it comes in a travel case with 30 tablets. Pharmacists should dispense an enclosed medication guide to each patient. The package includes NDC 70165-030-30 and Rx Only labels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.